問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Nuclear Medicine

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation
Far Eastern Memorial Hospital
國立臺灣大學醫學院

更新時間：2025-09-23

沈盈君Shen, Ying-Chun
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

146Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈盈君

List

242Cases

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multicenter, randomized trial comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer

  • Condition/Disease

    rPFS was defined as the time elapsed from the date of randomization to the date of the first documented radiographic disease progression or death from any cause as assessed by the Blinded Independent Central Review Committee (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3) revised RECIST version 1.1 criteria, whichever occurred first.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

2025-08-18 - 2030-06-30

Phase I/II

Active
A phase 1/2, open-label, multicenter trial of ALE.P03 (Claudin-1 targeted antibody-drug complex) monotherapy in selected adult patients with advanced or metastatic CLDN1+ solid tumors.

  • Condition/Disease

    Advanced or metastatic CLDN1+ solid tumors

  • Test Drug

    ALE.P03

Participate Sites
4Sites

Recruiting4Sites

2025-01-21 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-09-24 - 2028-11-30

Phase I

Active
A first-in-human, phase 1, open-label, multicenter trial of a novel phosphatidylinositol glycan-3 target antibody-drug complex, ZW251, in participants with advanced solid tumors including hepatocellular carcinoma.

  • Condition/Disease

    Including advanced solid tumors such as hepatocellular carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2024-10-01 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

  • Condition/Disease

    Gastrointestinal Cancer

  • Test Drug

    Injectable

Participate Sites
3Sites

Recruiting3Sites

2024-11-01 - 2029-12-31

Phase III

Active
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Injectable solution Injectable preparation Injectable preparation

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    Tablets Soft capsules Infusion solutions

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2035-08-31

Phase III

Active
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

  • Condition/Disease

    Metastatic Castration Sensitive Prostate Cancer (mCSPC)

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Recruiting6Sites

2019-05-01 - 2029-12-31

Phase III

Completed
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2025-10-01 - 2029-06-30

Phase III

Active
A phase 3, randomized, multicenter, open-label study was conducted to investigate the use of IDRX-42 (GSK6042981) versus Sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who had received imatinib treatment (StrateGIST 3).

  • Condition/Disease

    Metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) following treatment with imatinib.

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB